Tag Archive | "benign prostatic hyperplasia"

No Relationship Found Between Weight Changes and LUTS


Even though obesity has been related to lower urinary tract symptoms (LUTS) in aging men, new findings from researchers at the Mayo Clinic College of Medicine in Rochester, Minnesota suggest that modest weight loss may not prevent the onset or progression of LUTS among these men.  Also, no relationship was found between weight gain and the development or progression of LUTS.

The research team analyzed data from 1,674 white men participating in the Olmstead County Study (OCS) of Urinary Symptoms and Health Status among Men, funded by Merck Research Laboratories, and 168 black men participating in the Flint Men’s Health Study.  Researchers separated the participants into three categories based on differences between their baseline weight and weight during four year of follow-up: no weight loss, less than 5% of baseline weight loss, and more than 5% of baseline weight loss.

Jennifer L. St. Sauver, Ph.D., the lead author of the study, reported at the American Urological Association annual meeting that participants in both studies and in all weight categories experienced no statistically significant change in LUTS.  Her research team found that in the OCS cohort, weight loss was not related to receipt of treatment for benign prostatic hyperplasia.  Dr. St. Sauver concludes that although weight loss can help prevent a number of diseases such as diabetes, modest weight loss may not prevent development of LUTS.  A report of the study will be published in Urology. Data collection for this study was additionally funded by grants from the National Institutes of Health.

Posted in Bladder HealthComments Off

Research Study for Treatment of Lower Urinary Tract Symptoms (LUTS) Due To Benign Prostatic Hyperplasia (BPH)


Are you a man age 50 or older?

Do you have to urinate frequently during the day and at night?

Do you have trouble urinating?

Are these and other urinary problems interfering with your life and your relationships?

If you answered “yes” to the above questions, you may be a candidate for the L.I.F.T. Study.

The L.I.F.T. Study is an FDA approved research study to evaluate the UroLift system to support a premarketing application to FDA.  Its purpose is to determine the safety and effectiveness of the UroLift system for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).  The study is being conducted at urology practices throughout the U.S., in Canada and in Australia.

BPH is a non cancerous condition that causes the prostate to enlarge as men age.  When the enlarged prostate presses on the urethra, it can cause bothersome urinary symptoms. The UroLift System is a minimally invasive approach to treating BPH that lifts/holds the enlarged prostate tissue out of the way so it no longer blocks the urethra.  There is no cutting, heating or removal of prostate tissue. The goal of UroLift system treatment is to relieve symptoms so you can get back to your life and resume your daily activities.

The UroLift system is an investigational device as such is limited by Federal Law to investigational use only.

To find out more about L.I.F.T. Study and UroLift system treatment and study locations, go to www.neotract.com.

Posted in Bladder TreatmentComments Off

Acute Urinary Retention Could Be Deadly


Urologists are finding that men with acute urinary retention, especially those with co-morbidities, are at a much higher risk of death.

One in seven men hospitalized with spontaneous acute urinary retention and one in four with precipitated acute urinary retention died within a year, according to a British population-based study published online in BMJ.

Jan H. P. van der Meulen, Ph.D., of the London School of Hygiene and Tropical Medicine reported, “Overall, one-year mortality was two to three times higher than for the general male population, and was substantially higher among men with co-morbid conditions.”

“Because mortality was highest in the presence of co-morbid conditions, people presenting with acute urinary retention should be given a urological examination and a multidisciplinary review to identify and treat co-morbidity early,” commented Katia M. C. Verhamme, M.D., and Miriam C. J. M. Sturkenboom, Pharm. D., Ph.D., both of the Erasmus Medical Center in Rotterdam, The Netherlands.

In Europe, the majority of urologists would hospitalize patients with acute urinary retention, explains Dr. van der Meulen and colleagues.  This is not the case in the United States.  Most patients are given a urinary catheter and sent home, commented J. Stephen Jones, M.D., of the Cleveland Clinic.

“Unfortunately, a severe limitation of the study is that they don’t define how many patients had retention but did not get admitted to hospital,” said Dr. Jones.  “Nevertheless, their focus is very much on target that the physicians should be aware that this could simply be a harbinger of other co-morbidities.”

Researchers used a national database for the study, analyzing over 170,000 men aged 45 or older who were admitted to National Health Services hospitals in England with a first episode of acute urinary retention between the years 1998 and 2005.

For those men who had spontaneous acute urinary retention as a primary diagnosis or accompanied with a primary diagnosis of benign prostatic hyperplasia, the one-year mortality was 14.7%.  Out of those participants with precipitated retention, 25.3% died within the first year after hospitalization.

And age was also a strong indicator of mortality risk.  One-year mortality increased from about 4% for 45- to 54-year-olds up to about 33% for those 85 or older.

Co-morbidity was determined to be a major factor in mortality.  If the patient had at least one co-morbid condition, his risk of dying within one year of hospitalization doubled in men aged 75 to 84.

But even patients without co-morbidity were at a higher risk of death than the general population.

Researchers of the study concluded that patients with acute urinary retention “are a vulnerable group and may benefit from urgent multidisciplinary care to identify and treat co-morbid conditions.”  This conclusion is especially applicable to the United States, where patients “often may not be getting multidisciplinary care,” Dr. Jones said.

“If urinary retention is the only presenting complaint, the urologist who is not as adept at handling systemic conditions or disease—high blood pressure, diabetes—may not focus as much on that as a medical physician,” concluded Dr. Jones.

Posted in FeatureComments Off